$CIEN — AVOID 📊 | 6 MONTHS THESIS

$CIEN — AVOID 📊 | 6 MONTHS THESIS 🧭 Conviction: HIGH 🎯 FQ2 FY2026 (ends May) | reported Jun 04 | Rev $1.6B | EPS $1.64 vs $1.46 🟢 | Margin 15.1% 💡 Consensus appears to extrapolate recent EPS beats indefinitely, but the stock's implied P/E of 73x and a reverse DCF that embeds -3.6% FCF growth suggest expectations are unsustainably high; any disappointment risks a sharp multiple compression toward historical norms. 🏢 Business Quality: 5/10 📊 Valuation: rich — trailing P/E 73x vs. peer band 7.4x–46.2x (median 18.7x); reverse DCF implies negative FCF growth; current price sits well above base and bear... 🔮 Catalyst: next quarterly earnings release ⚖️ Avoid CIEN: 73x trailing P/E, negative implied FCF growth, bottom-tile quant scores, and a 0.5:1 reward/risk profile leave no case for a long position.

🧭 Conviction: HIGH